Board of Directors


Hojabr Alimi, Chairman, CEO

Mr. Alimi has over 20 years of experience in the healthcare industry and has raised more than $170 million in capital throughout his career for different ventures. In 1999, he founded Micromed Laboratories Inc. to assist drug and device companies to navigate FDA and European Conformity (“CE”) mark approval processes. In 2002, Mr. Alimi founded Oculus Innovative Sciences, Inc., a company focused on topical anti- infective drugs as well as device-related applications. As CEO and Chairman, he led the company to successfully complete a randomized, double-blind, controlled phase II trial for improvement or cure of infection in diabetic ulcers.  Under his tenure, the company became publicly traded on Nasdaq and achieved dozens of regulatory approvals, including CE marks and 510(K) FDA clearances. In 2012, he founded Ruthigen, Inc. to focus on the development of a drug compound for the reduction of hospital acquired infections during invasive abdominal procedures. As CEO, Chairman and CSO, Ruthigen, Inc. completed an initial public offering and traded on NASDAQ, and later merged with Pulmatrix, a pulmonary-focused pharmaceutical company. Hoji Alimi holds more than 30 patents in areas of anti-infective, surgical, wound care and manufacturing of specific drugs and devices.   He received his B.A. in Biology - Sonoma State University 1995

 

G. Sridhar Prasad, PhD, CSO

Dr Prasad has been a member of drug discovery teams that discovered multiple drug candidates advanced to various stages of preclinical and clinical development, including Merck’s MK-4965. He was the lead crystallographer and core member of the team that discovered Alogliptin - A Syrrx and Takeda San Diego's DPP4 inhibitor being marketed under the brand name Nesina® to treat type 2 diabetes and the first drug to be discovered using structure-based design at Syrrx. He designed, built and implemented fragment-based crystallography drug discovery technology platforms at Syrrx, Merck and Metabasis. He has co-authored over 40 peer-reviewed research articles and holds 6 US and international patents. He serves on the editorial board of Current Protein and Peptide Science, Chemical Sciences Journal and Organic and Medicinal Chemistry International Journal. Dr. Prasad obtained his PhD from the Indian Institute of Science, Bangalore, India and post-doctoral training at the University of Minnesota Medical School and the Scripps Research Institute, La Jolla, California, where he was Assistant Professor.

 

William H. Watson, III, Vice-President of Global Sales and Business Development

William Watson’s career stems from over 30 years in finance and has grown to provide pivotal business development strategy and implementation for Collidion, Inc. Mr. Watson has been a registered representative and registered principal with FINRA since the early 1980’s. From 2003 to 2007, he joined Brookstreet Securities as the Vice President of Corporate Finance, where he completed 21 engagements totaling over $250 million of private placements, PIPE transactions, initial public offerings, and secondary offerings for small capitalization growth companies.  He has completed an additional $100 million of financing in his career for a variety of other ventures. In addition to financing activities, he also assisted in the assembly of Collidion’s scientific advisory board, interfaced with the board of directors and management, and generated key business development leads with healthcare partners. Since 2013, Mr. Watson has served on the Board of Directors of the National Investment Bankers Association.